Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief

After reporting the first patient dosed in September 2025, early clinical data from a small open-label study indicate that Enveda’s oral candidate, discovered via the company’s PRISM AI platform, ENV-294, produced rapid reductions in disease severity and itch in patients with moderate-to-severe atopic dermatitis, alongside a safety profile without serious adverse events.